Full-Time

Loss Prevention Manager

Posted on 1/24/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Croydon, UK

In Person

Category
Operations & Logistics (1)
Required Skills
Data Analysis
Requirements
  • Excellent Operational process knowledge
  • Strong leadership and interpersonal skills
  • Excellent written and verbal communication skills
  • Solution Mindset from working in a fast-paced customer centric organization
  • Leading and directing investigations into stock loss including interviewing colleagues
  • Detailed GDP knowledge and experience in assuring compliance to standards frameworks
  • Working knowledge of security systems (CCTV, access control & Intruder alarms)
  • Microsoft applications
  • Managing change
  • Experience in managing a stock control function in a similar position
  • Named on a Controlled drugs license (requires enhanced DBS Check) for witnessed destruction of controlled drugs
  • Working to Home Office controlled drugs standards, GDP green guide, MHRA (Medicines Healthcare regulatory agency)
  • Ensuring site security standards are to the expected standard and maintenance of the same
  • To support the Service Centre Senior Management team as part of the Duty Manager rota process
Responsibilities
  • Proactively and reactively manage risk to people and stock with an analytical, continuous improvement approach.
  • Support the delivery of stock management Key Performance Indicators by the Service Centre General Manager whilst maintaining an independent scrutiny to ensure this is achieved in the correct way.
  • Ensure our stock accuracy and processes are maintained at the highest standard supporting the development of corrective actions where exceptions are identified.
  • Ensure that Inventory team cost and specific overheads fall within budget through the implementation of robust control mechanisms.
  • Ensure compliance to Upstream Customer contractual requirements through the achievement of specific KPIs.
  • Ensure all inventory related tasks are performed satisfactorily and within required time windows.
  • Validate and investigate count overrides and stock discrepancies, escalating to the Service Centre General Manager
  • Effectively manage the reconciliation of supplier credit claims and uplifts.
  • Validate the correct processing, recording and where appropriate the destruction of products.
  • Validate the quarantine process through regular review of the lines held in quarantine, minimising this value through effective investigation and escalation.
  • Organise company or mandatory Upstream Customer supplier stock takes in line with requirements.
  • Validate that product batch recalls are dealt with promptly by Warehouse Operations Team.
  • Provide prompt feedback to customer related queries.
  • Maintain Integrity of the discontinued line process
  • Coaching and training SC team in all areas relating to stock management.
  • Ensure effective liaison with Central functions, Head office personnel, other Service Centres, suppliers and customers both upstream and downstream.
  • Maintain the security protection of the site and all related assets –eg Link points, vans, CCTV, access control, intruder alarms etc
  • Co-ordinate onsite and outbased searches including adherence to our Search Policy and targets.
  • Management of New User set up and authority levels
  • Theft investigation and supporting with investigation and disciplinary training.
  • Regular Planned Preventative Maintenance of Key Security assets within agreed timeframes
  • Assure compliance to legislative and regulatory requirements through the implementation of best practice (GDP SOP’s), audits and monitoring as per the stipulated guidelines by MHRA, Home Office, Police and Fire Authorities.
  • Lead external audits of GDP compliance in conjunction with the SC manager.
  • Generate and monitor the progress of Q Pulse responses to audits
  • Organise regular qualitive audits and report on findings to stakeholders
  • Ensure compliance to GDP requirements and attend daily, weekly and monthly meetings
  • Chair Monthly Loss Prevention Meeting focusing on Loss issues and KPIs
  • Responsible for the Warehouse Temperature Monitoring system with support from Service Centre Management Teams
  • Ensure compliance to Local outsourced GDP activities including regular Service Provider Audits
  • Maintain the SC business continuity plan on behalf of the SCM.
  • Work within the AH pillar framework to drive a culture of continuous improvement with high standard of inventory accuracy
  • Proactively use data to develop insights on stock discrepancy patterns in data with qualitive prevention actions.
  • Develop and maintain relevant knowledge across many aspects of the business as demand changes
  • Provide effective leadership and motivation through regular team briefings.
  • Attend and actively take part in the daily SC leadership meeting and the weekly Loss Prevention Manager meetings and to chair the meeting(s) as required.
  • Management of Inventory costs within targets
  • Monitor productivity performance and agreed KPIs with Service Centre General Manager.
  • Ensure the Service Centre meet all H&S requirements and direct reports understand their responsibilities
  • Provide Effective Leadership and motivation through regular team briefings
  • Provide coaching and guidance in areas of responsibility

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE